GlaxoSmithKline Rating Reiterated by Panmure Gordon (GSK)
GlaxoSmithKline (LON:GSK)‘s stock had its “buy” rating reiterated by analysts at Panmure Gordon in a research report issued to clients and investors on Monday, American Banking News reports. They currently have a GBX 1,850 ($29.93) target price on the stock. Panmure Gordon’s target price points to a potential upside of 15.30% from the company’s current price.
A number of other firms have also recently commented on GSK. Analysts at UBS AG reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Wednesday, October 16th. They now have a GBX 1,745 ($28.23) price target on the stock. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of GlaxoSmithKline in a research note to investors on Wednesday, October 16th. They now have a GBX 1,850 ($29.93) price target on the stock. Finally, analysts at Barclays reiterated an “equal weight” rating on shares of GlaxoSmithKline in a research note to investors on Tuesday, October 15th. They now have a GBX 1,555 ($25.16) price target on the stock. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. GlaxoSmithKline has a consensus rating of “Hold” and a consensus price target of GBX 1,630.52 ($26.38).
GlaxoSmithKline (LON:GSK) traded up 0.47% on Monday, hitting GBX 1604.50. 8,907,243 shares of the company’s stock traded hands. GlaxoSmithKline has a 52-week low of GBX 1314.00 and a 52-week high of GBX 1816.00. The stock has a 50-day moving average of GBX 1596. and a 200-day moving average of GBX 1649.. The company’s market cap is £77.289 billion.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.